New study questions claims of Avandia's heart risk
It is too soon to write off GlaxoSmithKline’s Avandia for type-2 diabetes, according to a new report by two US cardiologists. - News - PharmaTimes
by Michael Day
https://www.pharmatimes.com/news/new_study_questions_claims_of_avandias_heart_risk_990613